Abeona Therapeutics Inc. (ABEO) Shares Gap Up Following Analyst Upgrade


The stock now has an average rating of "Buy" and a consensus target price of $20.13.

Citigroup has just issued a Buy rating for Abeona Therapeutics (NASDAQ:ABEO) shares. The stock presently has a consensus rating of Buy and an average target price of $21.44.

Abeona Therapeutics Inc. (ABEO)'s RSI (Relative Strength Index) is 68.81. Maxim Group maintained Abeona Therapeutics Inc (NASDAQ:ABEO) on Wednesday, August 16 with "Buy" rating. As per Tuesday, August 29, the company rating was maintained by Maxim Group.

At the end of June reporting period, 37 institutional holders increased their position in Abeona Therapeutics Inc. The rating was maintained by Cantor Fitzgerald on Monday, September 25 with "Buy". H.C. Wainwright maintained it with "Buy" rating and $20.0 target in Friday, September 8 report.

10/9/2017-HC Wainwright Reiterated Rating of Buy.

W.W. Grainger, Inc.is a distributor of maintenance, fix and operating (MRO) supplies and other related services and products. The company has market cap of $146.47 billion. The Firm offers its services and products to businesses and institutions in the United States and Canada, with presence also in Europe, Asia and Latin America. It has a 22.44 P/E ratio. Out of 3 Wall Street analysts rating Grainger, 1 give it "Buy", 1 "Sell" rating, while 1 recommend "Hold". A score of nine indicates a high value stock, while a score of one indicates a low value stock.

On 7/31/2015 Mark J Ahn, Director, bought 18,182 with an average share price of $5.50 per share and the total transaction amounting to $100,001.00. The company was initiated on Friday, September 15 by RBC Capital Markets. The stock of W W Grainger Inc (NYSE:GWW) has "Hold" rating given on Wednesday, October 19 by Stifel Nicolaus. Similar statistics are true for the second largest owner, Adage Capital Partners Gp, L.L.C., which owns 1,950,000 shares of the stock are valued at $34.13 million. Golub Gru owns 32,361 shares or 0.08% of their U.S. portfolio. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company's stock valued at $210,000 after acquiring an additional 23,358 shares during the period. The Japan-based Mu Investments Co. Investors may use Price to Book to display how the market portrays the value of a stock. Citigroup, New York-based fund reported 6.07 million shares.

About 936,445 shares traded. General Electric Company (NYSE:GE) has declined 4.46% since October 10, 2016 and is downtrending.

Analysts await W W Grainger Inc (NYSE:GWW) to report earnings on October, 17 before the open. 1 firm rating the stock a strong buy, 3 brokers rating the stock a buy, 0 equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $12.38.

Analysts expect Abeona Therapeutics Inc (NASDAQ:ABEO) to report $-0.16 EPS on November, 13.They anticipate $0.08 EPS change or 100.00 % from last quarter's $-0.08 EPS. The company's shares were assimilated at $5.5 per share worth to an investment of some $110,000 on account of Wider Todd. It has outperformed by 134.32% the S&P500.

Abeona Therapeutics Inc. focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital. Checking in on some other ratios, the company has a Price to Cash Flow ratio of -39.135309, and a current Price to Earnings ratio of -30.800124. It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy for rare blood diseases.